The novel apolipoprotein A5 is present in human serum, is associated with VLDL, HDL, and chylomicrons, and circulates at very low concentrations compared with other apolipoproteins.

BACKGROUND The recently discovered apolipoprotein A5 (ApoA5) is fast gaining attention as a key regulator of serum triglyceride concentrations. An ApoA5 mouse knock-out model produced an approximately fourfold increase in serum triglycerides, whereas a knock-in model with human ApoA5 produced 50-70% lower concentrations of mouse serum triglycerides. In addition, peroxisome proliferator-activated receptor-alpha agonists, which are used clinically to lower serum triglyceride concentrations, cause increased ApoA5 mRNA expression. Despite these compelling molecular biology data, relatively little is known about ApoA5 protein in human serum. METHODS To better understand circulating concentrations and lipoprotein particle distribution of ApoA5, we expressed the recombinant human ApoA5 protein and raised antibodies against both the NH(2) and COOH termini. RESULTS Using the above reagents, we demonstrate for the first time that ApoA5 is present in human serum, although at much lower concentrations than other apolipoproteins such as ApoA1. Using a dual-antibody sandwich ELISA that we developed, we observed ApoA5 concentrations in human serum ranging from 24 to 406 microg/L compared with approximately 1 g/L for ApoA1. We also examined the lipoprotein particle distribution of ApoA5 and found that ApoA5 was detectable in VLDL, HDL, and chylomicrons, but not LDL. CONCLUSIONS These data demonstrate for the first time that ApoA5 is a secreted protein present in human serum and is associated with specific lipoprotein particles. In addition, our data indicate that the circulating concentration of human ApoA5 is very low compared with other apolipoproteins.

[1]  K. V. van Dijk,et al.  ApoAV Reduces Plasma Triglycerides by Inhibiting Very Low Density Lipoprotein-Triglyceride (VLDL-TG) Production and Stimulating Lipoprotein Lipase-mediated VLDL-TG Hydrolysis* , 2004, Journal of Biological Chemistry.

[2]  L. Pennacchio,et al.  Analysis of Apolipoprotein A5, C3, and Plasma Triglyceride Concentrations in Genetically Engineered Mice , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[3]  L. Havekes,et al.  The role and mode of action of apolipoproteins CIII and AV: synergistic actors in triglyceride metabolism? , 2004, Current opinion in lipidology.

[4]  Huadan Xue,et al.  Genetic effect of two polymorphisms in the apolipoprotein A5 gene and apolipoprotein C3 gene on serum lipids and lipoproteins levels in a Chinese population , 2004, Clinical genetics.

[5]  M. Nieminen,et al.  APOA5 gene variants, lipoprotein particle distribution, and progression of coronary heart disease: results from the LOCAT study. , 2004, Journal of lipid research.

[6]  D. Nickerson,et al.  Association of apolipoprotein A5 variants with LDL particle size and triglyceride in Japanese Americans. , 2004, Biochimica et biophysica acta.

[7]  X. Adiconis,et al.  The APOA5 locus is a strong determinant of plasma triglyceride concentrations across ethnic groups in Singapore Published, JLR Papers in Press, September 1, 2003. DOI 10.1194/jlr.M300251-JLR200 , 2003, Journal of Lipid Research.

[8]  J. W. Gallagher,et al.  Structure and Interfacial Properties of Human Apolipoprotein A-V* , 2003, Journal of Biological Chemistry.

[9]  D. Evans,et al.  The single nucleotide polymorphism −1131T>C in the apolipoprotein A5 (APOA5) gene is associated with elevated triglycerides in patients with hyperlipidemia , 2003, Journal of Molecular Medicine.

[10]  K. Chien,et al.  A novel genetic variant in the apolipoprotein A5 gene is associated with hypertriglyceridemia. , 2003, Human molecular genetics.

[11]  C. Broderick,et al.  Glucose Stimulates the Tyrosine Phosphorylation of Crk-associated Substrate in Pancreatic β-Cells* , 2003, Journal of Biological Chemistry.

[12]  X. Prieur,et al.  The Human Apolipoprotein AV Gene Is Regulated by Peroxisome Proliferator-activated Receptor-α and Contains a Novel Farnesoid X-activated Receptor Response Element* , 2003, Journal of Biological Chemistry.

[13]  Medha Kulkarni,et al.  Genetic analysis of a polymorphism in the human apoA-V gene: effect on plasma lipids. , 2003, Journal of lipid research.

[14]  L. Pennacchio,et al.  Apolipoprotein A5, a Crucial Determinant of Plasma Triglyceride Levels, Is Highly Responsive to Peroxisome Proliferator-activated Receptor α Activators* , 2003, The Journal of Biological Chemistry.

[15]  B. Tomlinson,et al.  APOA5‐1131T>C polymorphism is associated with triglyceride levels in Chinese men , 2003, Clinical genetics.

[16]  C. Kay,et al.  Structure-function studies of human apolipoprotein A-V: a regulator of plasma lipid homeostasis. , 2003, Biochemistry.

[17]  P. Talmud,et al.  Contribution of APOA5 gene variants to plasma triglyceride determination and to the response to both fat and glucose tolerance challenges. , 2003, Biochimica et biophysica acta.

[18]  J. Hubacek,et al.  T-1131-->C polymorphism within the apolipoprotein AV gene in hypertriglyceridemic individuals. , 2003, Atherosclerosis.

[19]  Len A Pennacchio,et al.  Apolipoprotein A5, a newly identified gene that affects plasma triglyceride levels in humans and mice. , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[20]  J. Ribalta,et al.  The Apolipoprotein AV Gene and Diurnal Triglyceridaemia in Normolipidaemic Subjects , 2003, Clinical chemistry and laboratory medicine.

[21]  O. eda,et al.  New Apolipoprotein A-V : Comparative Genomics Meets Metabolism , 2003 .

[22]  Shotai Kobayashi,et al.  The genetic effect of the apoprotein AV gene on the serum triglyceride level in Japanese. , 2002, Atherosclerosis.

[23]  Jonathan C. Cohen,et al.  Two independent apolipoprotein A5 haplotypes influence human plasma triglyceride levels. , 2002, Human molecular genetics.

[24]  S. Tomura,et al.  Association found between the promoter region polymorphism in the apolipoprotein A-V gene and the serum triglyceride level in Japanese schoolchildren , 2002, Human Genetics.

[25]  J. Ribalta,et al.  Newly identified apolipoprotein AV gene predisposes to high plasma triglycerides in familial combined hyperlipidemia. , 2002, Clinical chemistry.

[26]  R. Chamuleau,et al.  Adenoviral overexpression of apolipoprotein A-V reduces serum levels of triglycerides and cholesterol in mice. , 2002, Biochemical and biophysical research communications.

[27]  Jonathan C. Cohen,et al.  An Apolipoprotein Influencing Triglycerides in Humans and Mice Revealed by Comparative Sequencing , 2001, Science.

[28]  P. Reitsma,et al.  Apolipoprotein A-V A NOVEL APOLIPOPROTEIN ASSOCIATED WITH AN EARLY PHASE OF LIVER REGENERATION* , 2001 .